LUND, SE / ACCESS Newswire / April 23, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Shanghai ...

FDA grants Chinese Shanghai Henlius Orphan Drug Designation in gastric cancer for Alligator's out-licensed candidate HLX22. Publication of Alligator's Annual Report for 2024 on 27 March 2025 ...

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce and focus all its attention on lead cancer drug mitazalimab as it prepares for phase 3 trials.

Alligator Bioscience (market cap: $8.9 million) reported its Q1 2025 earnings, highlighting ongoing clinical trial expenses and a significant stock price drop of 6.21% to 4.941 SEK. Despite the ...

Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options. The Swedish ...

LUND, SE / ACCESS Newswire / April 23, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Shanghai Henlius Biotech, Inc. ("Henlius") has initiated a Phase 2 clinical trial ...

FDA grants Chinese Shanghai Henlius Orphan Drug Designation in gastric cancer for Alligator's out-licensed candidate HLX22. Publication of Alligator's Annual Report for 2024 on 27 March 2025, ...

Alligator Bioscience (market cap: $8.9 million) reported its Q1 2025 earnings, highlighting ongoing clinical trial expenses and a significant stock price drop of 6.21% to 4.941 SEK. Despite the ...

LUND, SE / / April 24, 2025 / Alligator Bioscience (STO:ATORX)24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab-three times higher than chemotherapy aloneFDA alignment ...

Zeit Aktuelle Nachrichten 12:02 Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc. LUND, SE / ACCESS Newswire / April 23, 2025 ...